Is Bio-Rad Laboratories Inc. (NYSE: BIO) Still On The Rise?

After Hours

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Bio-Rad Laboratories Inc. (BIO) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$3.79, or -0.70%, to $535.05. Volume reached 15,191 shares, with price reaching a high of $538.84 and a low of $538.84. Yahoo Finance discussed the stock recently as it posted Bio-Rad Acquires Curiosity Diagnostics.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

Stocks Info

This NYSE-listed company operates within the Medical Devices industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $538.84 and fluctuated between $550.18 as its day high and $534.61 as its day low. The current market capitalization of Bio-Rad Laboratories Inc. is $15.36B. A total of 0.1 million shares were traded on the day, compared to an average of 190.19K shares.

Insider Activity

Insider trades can also provide insight into a stock’s future direction. During the recent three months, BIO has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 32 BUYs and 36 SELLs from insiders. Insiders purchased 24,386 shares during that period but sold 18,524.

In the most recent transaction, TUMOLO ANNETTE sold 4,800 shares of BIO for 750.05 per share on Nov 12. After the transaction, the Executive Vice President now owns 4,593 company shares. In a previous transaction on Nov 11, TUMOLO ANNETTE sold 1,546 shares at 749.00 per share. BIO shares that Executive Vice President owns now total 4,593.

Among the insiders who sold shares, Daskal Ilan disposed of 270 shares on Sep 03 at a per-share price of $820.06. This resulted in the EVP, Chief Financial Officer holding 9 shares of BIO after the transaction. In another insider transaction, Daskal Ilan sold 540 shares at $828.00 per share on Sep 02. Company shares held by the EVP, Chief Financial Officer now total 7.

Dividend

The income generated by dividends is an indication that a company is improving its financial position, which is why investors prefer companies paying dividends.

Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for BIO in the last 3 months, the mean price target is $700.00 with high estimates of $700.00 and low estimates of $700.00. In terms of 52-week highs and lows, BIO has a high of $832.70 and a low of $462.61.

As of this writing, BIO has an earnings estimate of $2.9 per share for the current quarter. EPS was calculated based on a consensus of 2 estimates, with a high estimate of $3.21 per share and a lower estimate of $2.59. The company reported an EPS of $3.38 in the last quarter, which was 37.4% higher than expectations of $2.46.

Balance Sheet Annually/Quarterly

In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects.

Analysts Opinion

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 5 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for BIO is Overweight with a score of 5.00. A total of 3 analysts rated the stock as Buy while 1 rated it as Overweight while 1 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles

294

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

The 5 Best Inflation Stocks for 2022

100% free. stop anytime no spam

Get our free report on the stocks that we recommend for investors who want to protect their portfolios from inflation.